KRAS and non-small cell lung carcinoma: In non-Sq NSCLC, KRAS G12C mutated tumors were enriched for high TMB ≥ 10 mutations/Mb (40% vs 33% vs 32% for KRAS non-G12C and WT, both p < 0.001) and for high PD-L1 expression (44% vs 38% for KRAS non-G12C and 29% for WT, both p < 0.001), whereas KRAS G12D mutated tumors had lower incidence of elevated TMB (24% with TMB ≥ 10 mutations/Mb) relative to other KRASm isoforms assessed (Fig. 4a, b and Table 1).